HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Methotrexate and actinomycin D chemotherapy in a patient with porphyria: a case report.

AbstractBACKGROUND:
Despite their broadly recommended use as chemotherapeutic agents, the porphyrogenicity of methotrexate and actinomycin D have not been confirmed. Accordingly, it is not known whether these agents are safe for use in patients with porphyria.
CASE PRESENTATION:
In this report, we present a case of an invasive mole with lung metastasis in a 49-year-old Japanese woman who had previously been diagnosed with acute intermittent porphyria at 27 years of age but had no recent history of acute intermittent porphyria attacks. Her serum human chorionic gonadotropin level was elevated 1 month after hysterectomy, and she was referred to our center for chemotherapy. After she received 100 mg of methotrexate, drug eruptions were observed starting on day 3 and grew progressively worse. Erythema and mucosal erosion spread throughout her body, whereupon she was administered prednisolone. In addition, our patient experienced febrile neutropenia and required granulocyte colony- stimulating factor treatment. No changes in our patient's urinary coproporphyrin or uroporphyrin levels were detected during this entire episode. Methotrexate was replaced by actinomycin D (0.5 mg/body intravenously on days 1-5 every 2 weeks). After five uneventful cycles of actinomycin D, our patient achieved and maintained a normal serum human chorionic gonadotropin level for 3 years.
CONCLUSIONS:
Methotrexate and actinomycin D did not induce acute porphyric attacks in this patient with acute intermittent porphyria; however, severe adverse effects were noted with methotrexate. Although further investigation is required, our data suggest that these agents are nonporphyrinogenic and can therefore be used to treat patients with comorbid porphyria.
AuthorsYukiko Mikami, Tomonori Nagai, Yousuke Gomi, Yasushi Takai, Masahiro Saito, Kazunori Baba, Hiroyuki Seki
JournalJournal of medical case reports (J Med Case Rep) Vol. 10 Pg. 9 (Jan 18 2016) ISSN: 1752-1947 [Electronic] England
PMID26781485 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
  • Antineoplastic Agents
  • Chorionic Gonadotropin
  • Dactinomycin
  • Methotrexate
Topics
  • Antibiotics, Antineoplastic (therapeutic use)
  • Antineoplastic Agents (administration & dosage, adverse effects)
  • Chorionic Gonadotropin (blood)
  • Dactinomycin (therapeutic use)
  • Drug Eruptions (drug therapy, etiology)
  • Female
  • Humans
  • Hydatidiform Mole, Invasive (drug therapy, secondary, surgery)
  • Hysterectomy
  • Lung Neoplasms (drug therapy, secondary)
  • Methotrexate (administration & dosage, adverse effects)
  • Middle Aged
  • Porphyria, Acute Intermittent (complications)
  • Pregnancy
  • Treatment Outcome
  • Uterine Neoplasms (drug therapy, pathology, surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: